BiondVax Pharmaceuticals announced a change of its corporate name to Scinai Immunotherapeutics. In the past two years, the Company has substantially revamped its senior management team and pharmaceuticals development programs and recently announced its expansion into the CDMO business under the banner Scinai Bioservices. The new corporate name, which was approved by the Israeli authorities on August 31, is the Companys latest step to better reflect its fresh start and new direction. Scinai and its new symbol, “SCNI”, will debut on Nasdaq tomorrow. The CUSIP of the Company’s ADSs will remain 09073Q204 after the Nasdaq symbol change to SCNI.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BVXV:
- BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological Therapeutics
- BiondVax files $150M mixed securities shelf
- BiondVax Reports Second Quarter Financial Results and Provides Business Update
- BiondVax reports Q2 EPS 0c vs 0c last year
- Nasdaq Grants BiondVax Extension to Regain Compliance with Listing Rules